FAM222A

Across TCGA pan-cancer cohorts, FAM222A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of FAM222A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FAM222A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FAM222A is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where FAM222A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM222A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.468	<.001	11	view →
LSCC	Female	II,III,IV	+0.936	<.001	8	view →
LUAD	Male	III,IV	+0.525	<.001	8	view →
HNSC	Male	III,IV	+0.454	<.001	8	view →
COAD	Male	III,IV	−0.404	.003	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

FAM222A–CCRCC

Open the CCRCC breakdown →